Details of the Drug Inactive Ingredient (DIG)

General Information of DIG (ID: E06RNC)
DIG Name	Tartaric acid
Synonyms	Click to Show/Hide the Synonyms of This DIG DL-Tartaric acid; tartaric acid; 2,3-Dihydroxysuccinic acid; 2,3-Dihydroxybutanedioic acid; 133-37-9; 526-83-0; Racemic acid; Uvic acid; Traubensaure; Racemic tartaric acid; DL-Tartrate; Paratartaric acid; Paratartaric aicd; Threaric acid; Resolvable tartaric acid; BUTANEDIOIC ACID, 2,3-DIHYDROXY-; (+)-Tartaric acid; Natural tartaric acid; Acidum tartaricum; NSC62778; Tartaric acid D,L; Tartaric acid, L-(+)-; Baros; CHEBI:15674; dl-2,3-dihydroxybutanedioic acid; Dextrotartaric acid; (2RS,3RS)-Tartaric acid; tartrate; MFCD00071626; NSC 148314; Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-rel-; E-7050 (2S,3S)-2,3-dihydroxysuccinic acid; (2R,3R)-rel-2,3-Dihydroxysuccinic acid; DL-Tartaric acid, 99.5%; Butanedioic acid, 2,3-dihydroxy-(R,R)-(.+/-.)-; Butanedioic acid, 2,3-dihydroxy-, (R,R)-; 868-14-4; Tartaric acid, L-; (2R,3R)-2,3-Dihydroxybernsteinsaeure; Tartaric acid (VAN); 1007601-97-9; Kyselina vinna [Czech]; NSC155080; Butanedioic acid, 2,3-dihydroxy- (2R,3R)-; Tartaric acid [USAN:JAN]; (.+-.)-Tartaric acid; C4H6O6; (+)-(2R,3R)-Tartaric acid; d-alpha,beta-Dihydroxysuccinic acid; NSC-62778; Kyselina 2,3-dihydroxybutandiova [Czech]; (+) tartaric acid; (-) tartaric acid; 1,2-Dihydroxyethane-1,2-dicarboxylic acid; AI3-06298; 1,2-dicarboxylic acid; WLN: QVYQYQVQ; (-) D-Tartaric acid; ACMC-209qpg; Sal tartar (Salt/Mix); Tartaric acid, (DL)-; Butanedioic acid, 2,3-dihydroxy- (R-(R,R))-; Butanedioic acid, 2,3-dihydroxy-, [S-(R,R)]-; Malic acid, 3-hydroxy-; laevo-(+)-tartaric acid; dextro,laevo-tartaric acid; Succinic acid,3-dihydroxy; SCHEMBL848; ACMC-209cz3; bmse000167; Succinic acid,3-dihydroxy-; (.+/-.)-Tartaric acid; DSSTox_CID_26986; DSSTox_RID_82036; 2,3-dihydroxy-succinic acid; DSSTox_GSID_46986; Oprea1_827092; TARTARIC ACID, (L); Tartaric acid, (.+-.)-; Butanedioic acid,3-dihydroxy-; CHEMBL333714; Dihydroxysuccinic acid, (DL)-; Tartaric acid, (.+/-.)-; DTXSID5046986; L+Tartaric Acid FCC, NF, USP; 2,3-bis(oxidanyl)butanedioic acid; HMS3370M15; DL-TARTARIC-2,3-D2 ACID; (+)-2,3-dihydroxybutanedioic acid; (S,S)-Tartaric acid;Tartaric acid; BCP14303; Tox21_302052; BBL011588; MFCD00064206; NSC133735; NSC148314; NSC608773; s2997; STK387106; 2,3-Dihydroxysuccinic acid, (DL)-; 3-carboxy-2,3-dihydroxypropanoic acid; AKOS000120086; AKOS016844048; MCULE-3867000095; NE11122; NSC-133735; NSC-148314; NSC-608773; SMP2_000051; d-.alpha.,.beta.-Dihydroxysuccinic acid; NCGC00256063-01; NCGC00347131-03; AK105884; AK116146; AS-10983; CAS-133-37-9; NCI60_001102; (+)-2,3-dihydroxy-1,4-butanedioic acid; DB-016129; DB-016159; DB-042899; AM20110247; FT-0624346; FT-0625514; FT-0628018; FT-0628243; FT-0656080; FT-0772946; FT-0773804; (+/-)-2,3-dihydroxy-1,4-butanedioic acid; 1467-EP2269610A2; 1467-EP2269986A1; 1467-EP2269988A2; 1467-EP2269989A1; 1467-EP2269990A1; 1467-EP2270003A1; 1467-EP2270006A1; 1467-EP2270008A1; 1467-EP2270011A1; 1467-EP2270014A1; 1467-EP2270505A1; 1467-EP2272516A2; 1467-EP2272537A2; 1467-EP2272822A1; 1467-EP2272827A1; 1467-EP2272835A1; 1467-EP2272843A1; 1467-EP2272844A1; 1467-EP2275401A1; 1467-EP2275411A2; 1467-EP2275413A1; 1467-EP2275414A1; 1467-EP2277507A1; 1467-EP2277848A1; 1467-EP2277858A1; 1467-EP2277866A1; 1467-EP2277867A2; 1467-EP2280003A2; 1467-EP2280009A1; 1467-EP2281559A1; 1467-EP2281563A1; 1467-EP2281817A1; 1467-EP2281819A1; 1467-EP2281823A2; 1467-EP2284149A1; 1467-EP2284160A1; 1467-EP2284169A1; 1467-EP2284178A2; 1467-EP2284179A2; 1467-EP2286795A1; 1467-EP2287147A2; 1467-EP2287154A1; 1467-EP2287155A1; 1467-EP2287156A1; 1467-EP2287160A1; 1467-EP2287161A1; 1467-EP2287162A1; 1467-EP2289510A1; 1467-EP2289518A1; 1467-EP2289879A1; 1467-EP2289883A1; 1467-EP2289885A1; 1467-EP2289890A1; 1467-EP2289893A1; 1467-EP2292227A2; 1467-EP2292231A1; 1467-EP2292234A1; 1467-EP2292592A1; 1467-EP2292611A1; 1467-EP2292612A2; 1467-EP2292617A1; 1467-EP2292619A1; 1467-EP2295055A2; 1467-EP2295402A2; 1467-EP2295406A1; 1467-EP2295414A1; 1467-EP2295416A2; 1467-EP2295418A1; 1467-EP2295424A1; 1467-EP2295433A2; 1467-EP2298731A1; 1467-EP2298734A2; 1467-EP2298735A1; 1467-EP2298742A1; 1467-EP2298746A1; 1467-EP2298747A1; 1467-EP2298748A2; 1467-EP2298755A1; 1467-EP2298758A1; 1467-EP2298759A1; 1467-EP2298763A1; 1467-EP2298767A1; 1467-EP2298768A1; 1467-EP2298772A1; 1467-EP2298777A2; 1467-EP2298779A1; 1467-EP2301544A1; 1467-EP2301922A1; 1467-EP2301931A1; 1467-EP2301937A1; 1467-EP2301940A1; 1467-EP2305219A1; 1467-EP2305248A1; 1467-EP2305257A1; 1467-EP2305633A1; 1467-EP2305636A1; 1467-EP2305641A1; 1467-EP2305646A1; 1467-EP2305651A1; 1467-EP2305653A1; 1467-EP2305655A2; 1467-EP2305659A1; 1467-EP2305663A1; 1467-EP2305664A1; 1467-EP2305672A1; 1467-EP2305673A1; 1467-EP2305675A1; 1467-EP2305676A1; 1467-EP2305679A1; 1467-EP2305683A1; 1467-EP2308839A1; 1467-EP2308841A2; 1467-EP2308849A1; 1467-EP2308850A1; 1467-EP2308851A1; 1467-EP2308854A1; 1467-EP2308857A1; 1467-EP2308861A1; 1467-EP2308869A1; 1467-EP2308871A1; 1467-EP2308872A1; 1467-EP2308873A1; 1467-EP2308875A1; 1467-EP2311453A1; 1467-EP2311801A1; 1467-EP2311802A1; 1467-EP2311803A1; 1467-EP2311807A1; 1467-EP2311809A1; 1467-EP2311810A1; 1467-EP2311811A1; 1467-EP2311818A1; 1467-EP2311821A1; 1467-EP2311831A1; 1467-EP2311834A1; 1467-EP2311837A1; 1467-EP2311839A1; 1467-EP2311842A2; 1467-EP2314295A1; 1467-EP2314574A1; 1467-EP2314575A1; 1467-EP2314576A1; 1467-EP2314584A1; 1467-EP2314585A1; 1467-EP2314586A1; 1467-EP2314587A1; 1467-EP2314588A1; 1467-EP2314589A1; 1467-EP2314593A1; 1467-EP2316457A1; 1467-EP2316458A1; 1467-EP2316459A1; 1467-EP2316470A2; 1467-EP2316825A1; 1467-EP2316826A1; 1467-EP2316827A1; 1467-EP2316828A1; 1467-EP2316829A1; 1467-EP2316831A1; 1467-EP2316832A1; 1467-EP2316833A1; 1467-EP2316834A1; 1467-EP2316835A1; 1467-EP2316836A1; 1467-EP2316837A1; 1467-EP2371814A1; 1467-EP2374454A1; 1467-EP2374780A1; 1467-EP2374781A1; 1467-EP2380874A2; A22830; A22866; Butanedioic acid,3-dihydroxy- [R-(R,R)]-; 133D379; A829202; Q194322; Butanedioic acid,3-dihydroxy-, (R,R)-(.+-.)-; F2191-0230; Z1258943354; 1,2-Dihydroxyethane-1,2-dicarboxylic acid;2,3-Dihydrosuccinic acid; (2S,3S)-(-)-Tartaric acid; D(-)-Threaric acid;D(-)-Dihydroxysuccinic acid; Copper, mixt. with [R-(R,R)]-2,3-dihydroxybutanedioic acid monopotassium salt; 91469-46-4
DIG Function	Acidulant; Complexing agent; Flavoring agent
PubChem CID	875
Formula	C4H6O6
Canonical SMILES	C(C(C(=O)O)O)(C(=O)O)O
InChI	1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)
InChIKey	FEWJPZIEWOKRBE-UHFFFAOYSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This DIG
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=875"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	150.09	Topological Polar Surface Area	115
	XlogP	-1.9	Complexity	134
	Heavy Atom Count	10	Rotatable Bond Count	3
	Hydrogen Bond Donor Count	4	Hydrogen Bond Acceptor Count	6

Full List of Active Pharmaceutical Ingredients (APIs) Co-administrated with This DIG
ICD Disease Classification 02		Benign/in-situ/malignant neoplasm	Click to Show/Hide
Temozolomide	API Info	Brain cancer [ICD-11: 2A00]		[1]
Topotecan	API Info	Ovarian cancer [ICD-11: 2C73]		[2]
ICD Disease Classification 05		Endocrine/nutritional/metabolic disease	Click to Show/Hide
Diethylpropion	API Info	Obesity [ICD-11: 5B81]		[3]
ICD Disease Classification 06		Mental/behavioural/neurodevelopmental disorder	Click to Show/Hide
Risperidone	API Info	Schizophrenia [ICD-11: 6A20]		[4]
Aripiprazole	API Info	Schizophrenia [ICD-11: 6A20]		[5]
ICD Disease Classification 07		Sleep-wake disorder	Click to Show/Hide
Zolpidem	API Info	Insomnia [ICD-11: 7A00]		[6]
ICD Disease Classification 08		Nervous system disease	Click to Show/Hide
Donepezil	API Info	Alzheimer disease [ICD-11: 8A20]		[7]
Methylergonovine	API Info	Migraine [ICD-11: 8A80]		[8]
ICD Disease Classification 10		Ear/mastoid process disease	Click to Show/Hide
Diphenhydramine	API Info	Meniere disease [ICD-11: AB31]		[9]
ICD Disease Classification 11		Circulatory system disease	Click to Show/Hide
Aspirin	API Info	Myocardial infarction [ICD-11: BA41]		[10]
Bosentan	API Info	Pulmonary hypertension [ICD-11: BB01]		[11]
Dabigatran etexilate	API Info	Venous thromboembolism [ICD-11: BD72]		[12]
ICD Disease Classification 13		Digestive system disease	Click to Show/Hide
Tacrolimus	API Info	Ulcerative colitis [ICD-11: DD71]		[13]
ICD Disease Classification 16		Genitourinary system disease	Click to Show/Hide
Oxybutynin	API Info	Overactive bladder [ICD-11: GC50]		[14]

References
1	FDA label for approved temozolomide from the official website of the U.S. Food and Drug Administration.
2	FDA label for approved topotecan from the official website of the U.S. Food and Drug Administration.
3	FDA label for approved diethylpropion from the official website of the U.S. Food and Drug Administration.
4	FDA label for approved risperidone from the official website of the U.S. Food and Drug Administration.
5	FDA label for approved aripiprazole from the official website of the U.S. Food and Drug Administration.
6	FDA label for approved zolpidem from the official website of the U.S. Food and Drug Administration.
7	FDA label for approved donepezil from the official website of the U.S. Food and Drug Administration.
8	FDA label for approved methylergonovine from the official website of the U.S. Food and Drug Administration.
9	FDA label for approved diphenhydramine from the official website of the U.S. Food and Drug Administration.
10	FDA label for approved aspirin from the official website of the U.S. Food and Drug Administration.
11	FDA label for approved bosentan from the official website of the U.S. Food and Drug Administration.
12	FDA label for approved dabigatran etexilate from the official website of the U.S. Food and Drug Administration.
13	FDA label for approved tacrolimus from the official website of the U.S. Food and Drug Administration.
14	FDA label for approved oxybutynin from the official website of the U.S. Food and Drug Administration.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.